The Cogstate Blog

Gather insights and guidance from the experts in cognitive measurement.

A4 Study Baseline Data Show C3 Computerized Battery has Potential as Proxy for Paper and Pencil Measures in AD Prevention Trials

A4 Study Baseline Data Show C3 Computerized Battery has Potential as Proxy for Paper and Pencil Measures in AD Prevention Trials

Results from the A4 study baseline assessments have identified that the Computerized Cognitive Composite (C3) battery has potential to serve as a proxy for paper and pencil measures in AD prevention trials. Cogstate’s CSO sat down with Dr. Kate Papp, the lead author of a recent publication showcasing C3 data.

July 10, 2020
AHRQ Systematic Review Classifies Cogstate Cognitive Tests as Highly Sensitive and Specific in Distinguishing Alzheimer’s Disease

AHRQ Systematic Review Classifies Cogstate Cognitive Tests as Highly Sensitive and Specific in Distinguishing Alzheimer’s Disease

A recent review of the cognitive tests available for identifying impairment related to Alzheimer’s disease and its very early stages ranked both the Cogstate Brief Battery (CBB) and the Cogstate International Shopping List Test in the highest bracket for sensitivity and specificity at distinguishing CATD from normal cognition.

May 18, 2020
Study Shows Scopolamine Challenge Test May be a Viable Screening Tool for Aβ-related Cognitive Decline in Preclinical Alzheimer’s Disease

Study Shows Scopolamine Challenge Test May be a Viable Screening Tool for Aβ-related Cognitive Decline in Preclinical Alzheimer’s Disease

While PET scanning will remain important, the scopolamine challenge test (SCT) may offer another method for understanding early AD related changes in people at risk for the disease.

April 15, 2020
Cogstate Computerized Cognitive Testing Receives High Patient Ratings in Diverse Primary Care Settings

Cogstate Computerized Cognitive Testing Receives High Patient Ratings in Diverse Primary Care Settings

Early detection of cognitive impairment in adults is important in planning care for Alzheimer’s Disease. Computerized assessment of cognition has the potential to be leveraged in mainstream primary care settings to efficiently and accurately test millions. Read the research results from SUNY.

March 5, 2020
Soccer Players Who Carry APOE ε4 Variant at Greater Risk from Frequent Heading

Soccer Players Who Carry APOE ε4 Variant at Greater Risk from Frequent Heading

JAMA Neurology published data from a recent study showing soccer players who head the ball more frequently experience episodic memory loss, as demonstrated by lower scores on the Cogstate International Shopping List Delayed Recall (ISRL) test.

February 12, 2020
Cogstate Celebrates 20 Years of Advancing Brain Health Assessment

Cogstate Celebrates 20 Years of Advancing Brain Health Assessment

Martyn Myer AO, Cogstate Chairman, reflects on the history of the company and neuroscience research in Australia.

December 12, 2019
Study Used Cogstate ISLT to Examine the Impact of Cannabis Use on Learning and Memory Function in Young Adults

Study Used Cogstate ISLT to Examine the Impact of Cannabis Use on Learning and Memory Function in Young Adults

Chosen by the researchers for its reliability across language translations and its validity for measuring verbal memory, the Cogstate ISLT assesses immediate and delayed recall of a 12-item list. Read how the ISLT was used by a multi-university team to study the impact of cannabis.

June 2, 2019
Review of Recent FDA Draft Guidance for Rare Disease Clinical Trials

Review of Recent FDA Draft Guidance for Rare Disease Clinical Trials

Dr. Pam Ventola reviews two recent FDA draft guidances for rare disease drug development in this video. Learn about the need for indication-specific outcomes, as well as how to get the most from natural history studies to determine acceptability/feasibility of endpoints and inform future trial designs.

April 22, 2019
Cogstate Battery Used to Assess Cognition in Traumatic Brain Injury Patients in Uganda

Cogstate Battery Used to Assess Cognition in Traumatic Brain Injury Patients in Uganda

In a study published in BMC Neurology, researchers enrolled patients who had been diagnosed with a recent TBI, along with healthy volunteers, to assess their neuropsychological function six months after the injured group had been admitted to the hospital. Learn how a Cogstate battery of computerized tests was used to assess six different areas of cognitive function and the results.

February 28, 2019
Cogstate Tests Show No Cognitive Impairment from Use of Lorlatinib for the Treatment of Non-Small-Cell Lung Cancer

Cogstate Tests Show No Cognitive Impairment from Use of Lorlatinib for the Treatment of Non-Small-Cell Lung Cancer

During the drug development process, it’s important to characterize the nature and magnitude of any adverse effects a drug may have on cognition, even if the underlying disease is not brain-related. Learn how a phase 2 study of Lorlatinib leveraged a Cogstate battery to test cognitive safety.

January 16, 2019
Reliable and Valid Cognitive Test Results Obtained from MS Patients Performing Self-Administered Computerized Assessment

Reliable and Valid Cognitive Test Results Obtained from MS Patients Performing Self-Administered Computerized Assessment

Cognitive dysfunction occurs in more than half of all people with multiple sclerosis (MS), and many wonder how technology can be used to facilitate early cognitive screening in a way that is efficient, reliable and low burden to patients. Read research findings that show how computerized neuropsychological tests can be leveraged in this manner.

December 19, 2018
Cogstate Battery Demonstrates Sensitivity in Detecting Therapy-related Changes in Pediatric Neuro-oncology Patients Undergoing Radiation Treatment

Cogstate Battery Demonstrates Sensitivity in Detecting Therapy-related Changes in Pediatric Neuro-oncology Patients Undergoing Radiation Treatment

Computerized cognitive assessments, like the Cogstate battery, offer advantages such as improved administration across examiners and settings, increased precision and reliability in measuring response time, repeatability due to alternate forms, reduced testing time and flexibility in terms of the testing environment.

December 16, 2018

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch